GeoVax Labs’ (GOVX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research note published on Thursday,Benzinga reports. They currently have a $18.00 price objective on the stock.

GeoVax Labs Stock Performance

Shares of NASDAQ GOVX opened at $1.02 on Thursday. The company has a 50 day simple moving average of $1.44 and a two-hundred day simple moving average of $1.99. GeoVax Labs has a fifty-two week low of $0.88 and a fifty-two week high of $11.18. The company has a market capitalization of $14.12 million, a price-to-earnings ratio of -0.18 and a beta of 3.70.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.38 million. On average, analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp bought a new stake in shares of GeoVax Labs during the fourth quarter valued at approximately $29,000. Virtu Financial LLC bought a new stake in shares of GeoVax Labs in the 3rd quarter worth $97,000. Citadel Advisors LLC purchased a new position in shares of GeoVax Labs in the fourth quarter worth $104,000. Finally, Geode Capital Management LLC lifted its holdings in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.